Pioneering CAR T in Autoimmune Diseases JP Morgan Healthcare Conference January 2026 Disclaimer and Forward-Looking Statements This presentation contains forward-looking statements that are based on management's beliefs and assumptions and information currently available to management of Kyverna Therapeutics, Inc. ("Kyverna", "we", "our," or the "Company"). All statements other than statements of historical facts contained in this presentation are forward-looking statements. Forward looking statements inclu ...

FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 08, 2026 Kyverna Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41947 83-1365441 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: ...

Advancing valuable commercial opportunity in stiff person syndrome (SPS) following landmark registrational data; Biologics License Application (BLA) submission anticipated in 1H 2026 First patient enrolled in registrational Phase 3 trial in generalized myasthenia gravis (gMG) Completed follow-on offering extends cash runway into 2028, expected to fully fund SPS BLA filing, commercial launch, and Phase 3 gMG trial Kyverna Board member, Christi Shaw, appointed as Executive Chairperson, further bolstering Co ...

EMERYVILLE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the J.P. Morgan 2026 Healthcare Conference in San Francisco on Wednesday, January 14th, 2026, at 9:45 a.m. PT. A live audio webcast of the presentation may be accessed via the Investors section of th ...

Core Insights - Kyverna Therapeutics is developing mivocabtagene autoleucel (miv-cel) as a CAR T-cell therapy for stiff person syndrome (SPS), a rare autoimmune disease with no FDA-approved treatments, potentially making it the first CAR T therapy approved for an autoimmune condition [1][4] Group 1: Study Results - Positive top-line data from the pivotal phase II study indicated that miv-cel achieved statistically significant and sustained improvements in overall disability, mobility, and stiffness in SPS patients [2] - The study met all primary and secondary endpoints, with a median improvement of 46% in the timed 25-foot walk (T25FW) test, which assesses walking ability and mobility [3][9] Group 2: Future Plans - Kyverna plans to file a biologics license application (BLA) for miv-cel in the first half of 2026, aiming for FDA approval as the first therapy for SPS [4][9] - The company is also conducting a phase II/III study for miv-cel in generalized myasthenia gravis (gMG), with interim data showing potential for durable, drug-free remission [7] Group 3: Financial Developments - In November, Kyverna secured a loan facility of up to $150 million with Oxford Finance, enhancing its financial flexibility for ongoing pipeline development [10]

I've only had one look at Kyverna Therapeutics ( KYTX ), and at that time a year ago, I had some reservations about their timelines and cash burn, ultimately landing on a "Hold" sentiment at theI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in this s ...

PresentationGood morning, and welcome to the Kyverna Therapeutics Investor Conference Call. [Operator Instructions] Please note that this call is being recorded.Jessica Serra Good morning, and thank you for joining today's conference call to discuss top line data from our KYSA-8 registrational trial of mivocabtagene autoleucel or miv-cel, formerly referred to as KYV-101 in patients with stiff person syndrome or SPS. Before we begin, I encourage everyone to visit the Investor Relations section of our website ...

Core Viewpoint - Kyverna Therapeutics, Inc. has announced a public offering of 13,333,333 shares at a price of $7.50 per share, aiming to raise approximately $100 million before expenses [1][2]. Company Overview - Kyverna Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases, with its lead candidate being miv-cel, an autologous CD19-targeting CAR T-cell therapy [5][6]. Offering Details - The public offering is expected to close on or about December 18, 2025, pending customary closing conditions [1]. - The underwriters have a 30-day option to purchase up to 1,999,999 additional shares at the public offering price [1]. Management and Underwriters - J.P. Morgan, Leerink Partners, Morgan Stanley, and Wells Fargo Securities are acting as joint book-running managers for the offering [2].

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Core Insights - Kyverna Therapeutics, Inc. is a biotechnology company focused on innovative therapies for autoimmune diseases, gaining market attention after Wells Fargo maintained an "Overweight" rating and raised its price target from $31 to $33 [1][6] Stock Performance - The stock has seen a significant increase in options trading activity, with 2,529 call options purchased in a single day, representing a 900% rise from the average daily volume of 253 call options, indicating growing investor interest [2][6] - Kyverna Therapeutics has a market capitalization of approximately $474 million, with a price-to-earnings (P/E) ratio of -2.90, indicating the company is not currently profitable [3] - The stock's beta of 3.65 suggests high volatility compared to the overall market, while the fifty-day moving average is $7.29 and the 200-day moving average is $5.06, showing a strong upward trend [3] Earnings Report - In its latest quarterly earnings report, Kyverna Therapeutics reported an earnings per share (EPS) of -$0.85, beating the consensus estimate of -$0.97 by $0.12, which may have contributed to the stock's recent price increase [4][6] - Analysts expect the company to post an EPS of -3.29 for the current year, indicating ongoing challenges in achieving profitability [4] Price Fluctuations - The stock experienced a 23.12% increase to $10.81, up by $2.03, with trading between $10.40 and $13.67, the latter being its highest price in the past year [5] - The lowest price over the past year was $1.78, highlighting the stock's volatile nature, with a trading volume of 18,535,737 shares [5]